Wodwala Woyamba Wothandizidwa mu Gawo II Phunziro mu Multiple Myeloma

A GWIRITSANI KwaulereKutulutsidwa 6 | eTurboNews | | eTN
Avatar ya Linda Hohnholz
Written by Linda Hohnholz

XNK Therapeutics AB lero yalengeza kuti wodwala woyamba adalandira chithandizo mu kafukufuku wachipatala wa Phase II pogwiritsa ntchito mankhwala a XNK a autologous natural killer (NK) opangidwa ndi selo limodzi ndi Sanofi's anti-CD38 antibody Sarclisa (Isatuximab).

"Kukhala ndi wodwala woyamba kuthandizidwa ndi ma cell a NK mu phunziro lachipatala ili ndi gawo lofunika kwambiri pa chitukuko chachipatala cha mtsogoleri wathu wa mankhwala," anatero Johan Aschan, CMO wa XNK Therapeutics. Phunziroli likuyenda bwino, ndipo tikuyembekezera mwachidwi zotsatira zake.

Wofufuza wapano woyambitsa, wotseguka, wosasinthika, woyendetsedwa, Gawo II phunziro ISA-HC-NK (EudraCT: 2020-000994-26) akuyerekeza XNK wotsogola wamankhwala ophatikizana ndi Sanofi's anti-CD38 antibody Isatuximab ndi Isatuximab yekha ngati chithandizo chophatikiza chotsatira. autologous stem cell transplantation mwa odwala omwe angopezeka kumene angapo myeloma. Kafukufuku wachipatala amachitika ku Karolinska University Hospital pamalo ake a Huddinge ndipo amaphatikizapo odwala 60 omwe ali ndi odwala 30 pa mkono uliwonse wa chithandizo.

Ponena za wolemba

Avatar ya Linda Hohnholz

Linda Hohnholz

Mkonzi wamkulu kwa eTurboNews zochokera ku eTN HQ.

Amamvera
Dziwani za
mlendo
0 Comments
Zolowetsa Pamakina
Onani ndemanga zonse
0
Mukufuna malingaliro anu, chonde yankhani.x
Gawani ku...